DYRK1A and disease of the tendon: Biosplice Therapeutics is currently developing SM04755, a CLK2 and dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor, as an experimental treatment for tendinopathy [251].